ThursdayJan 25, 2024 1:46 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), lead teams that have collaborated with Scinai in the discovery of nanosized VHH antibodies (NanoAbs). These NanoAbs form the basis of Scinai's innovative, derisked pipeline. In announcing the award, MPI-NAT noted that Görlich received the recognition for "discovering a new kind of biological matter that…

Continue Reading

WednesdayJan 24, 2024 3:19 pm

BioMedNewsBreaks — Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the United States... In vitro studies have demonstrated the ability of Sigyn Therapy to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma… Sigyn designed the ImmunePrep platform to leverage the use of therapeutic antibodies…

Continue Reading

FridayJan 19, 2024 2:00 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024…

Continue Reading

FridayJan 19, 2024 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a highly accomplished biopharmaceutical industry executive, will join the company’s board effective upon completion of financing. With more than 20 years of experience working with large and small companies in common and rare conditions, Mahery brings impressive expertise in the commercialization and launch of drugs in varied therapeutic areas, including oncology, neurology, and immunology, to her new responsibilities.…

Continue Reading

ThursdayJan 18, 2024 1:01 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has completed enrollment in its global potentially pivotal study evaluating Berubicin. According to the announcement, the study has enrolled 247 patients across 46 clinical trial sites in the United States, Italy, France, Spain and Switzerland. A novel anthracycline, Berubicin appears to be the first anthracycline to cross the blood-brain barrier for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. The Berubicin study is a multicenter, open-label, randomized controlled study…

Continue Reading

TuesdayJan 16, 2024 3:26 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations and filed a motion to dismiss the lawsuit. On Jan. 8, 2024, the court denied the motion to dismiss, which means only that FSD Pharma will now proceed with discovery. The company is confident that…

Continue Reading

TuesdayJan 16, 2024 2:38 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and age-related macular degeneration (‘AMD’),” said Eric A. Adams, InMed president and CEO.…

Continue Reading

TuesdayJan 16, 2024 2:27 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership with NVIDIA to expand its multiomic capabilities to multimodal; and consistently achieving “the holy grail of cancer research” in preclinical studies. The company has also scheduled a shareholder meeting on Jan. 25, 2024, to vote…

Continue Reading

FridayJan 12, 2024 2:30 pm

BioMedNewsBreaks — Bruush Oral Care Inc. (NASDAQ: BRSH) Closes Private Placement, Enters into Purchase Agreement

Bruush Oral Care (NASDAQ: BRSH), an oral-care company that is disrupting the space by reducing the barriers between consumers and access to premium oral-care products, has closed on a private placement transaction and a registration rights agreement with Generating Alpha Ltd. for aggregate gross proceeds of $500,000; the company also entered into another securities purchase agreement with Generating Alpha. According to the filing with the U.S. Securities and Commission, Bruush Oral Care has agreed to sell a convertible promissory note in an aggregate principal amount of up to $6 million. EF Hutton acted as placement agent for the financing. To…

Continue Reading

FridayJan 12, 2024 2:09 pm

BioMedNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Partners with Navix Health to Provide Next-Generation Digital Healthcare Platform

SOBRSafe (NASDAQ: SOBR), a company that is pioneering noninvasive, humane and hygienic alcohol detection with a priority on safety, support and accountability, has been selected by Navix Health, a leading provider of innovative healthcare technologies, as its exclusive alcohol data partner. According to the announcement, Navix Health will integrate SOBRsafe's advanced alcohol monitoring technology into its proprietary Navix Hub(TM). The exclusive hub is a fully unified facility and practice management software for behavioral health. The integration of the SOBRsafe technology, which will enable Navix Hub users to augment current operations with touch-based alcohol monitoring, is aimed to enhance patient care,…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000